The Role Of Blood Neutrophil / Lymphocyte Distribution in The Diagnosis Of Prostate Cancer

• Main Authors: Deniz, M. Eflatun, Erçil, Hakan, Alma, Ergün, Tümer, Erbay, Altunkol, Adem, Unal, Umut, Gürbüz, Zafer Gökhan
• Format: Article
• Language: English
• Published: Ali İhsan Taşçı 2020-06-01
• Series: Yeni Üroloji Dergisi
• Subjects: neutrophil lymphocyte ratio (nlr); prostate cancer; diagnostic marker
• Online Access: https://dergipark.org.tr/tr/download/article-file/1102579

Objective: Neutrophil to lymphocyte ratio (NLR) is a recently popular diagnostic marker. We sought answers to questions such as whether this marker has a role in the diagnosis of prostate cancer, any cut off value can be calculated, compared to platelet lymphocyte ratio (PLR) and it has a relationship with Gleason score and percentage of tumors detected in biopsy cores. In addition, we aimed to share the findings of patients undergoing transrectal ultrasound (TRUS) guided biopsy. Materials and Methods: The results of 679 patients who underwent TRUS-guided prostate biopsy with prostate specific antigen (PSA) values above 2.5 ng / ml in our clinic between August 2014 and February 2017 were retrospectively analyzed. Patients were between 2.5-3.9 ng / ml (Group 1), 4-9.9 ng / ml (Group 2), 10-19.9 ng / ml (Group 3), 20 ng / ml and above (Group 4) according to PSA values, divided into four groups. The diagnostic value of NLR was evaluated in these groups. Results: NLR was found as a diagnostic marker in groups 2,3 and 4. The cut off value was calculated as 2.5. It had similar diagnostic power as PLR. There was a poor correlation with Gleason score and percentage of tumor in cores. It was not important in predicting bone metastasis. The difference between PSA density and DRE was statistically significant in groups with pathologic prostate cancer (PCa) or benign prostatic hyperplasia (BPH). Conclusion: Although NLR is not very strong in the diagnosis of PCa, it has a diagnostic value. It can be used as a marker to support PSA.